Dr. John Axelson

Dr. Dale Bixby has been practicing hematology at the University of Michigan since 2009. He obtained his PhD in Medicinal Chemistry and Pharmaceutics at the University of Kentucky in 1999, before beginning his medical training at the University of Michigan in Ann Arbor, MI. He was a resident in the Department of Internal Medicine and then completed fellowship training in hematology and medical oncology at the University of Michigan. Dr. Bixby is currently a clinical professor and specializes in the areas of myeloid and lymphoid leukemias, myelodysplastic syndrome and bone marrow failure disorders. Dr. Bixby currently serves as the section chief of the acute leukemia program. He is also a clinical investigator in hematological malignancies. Dr. Bixby is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Bixby is board certified in Hematology.

Erica Campagnaro is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Campagnaro is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Campagnaro is board certified in Internal Medicine and Hematology.

Dr. Pettit studied physics and magazine journalism at Syracuse University prior to earning her MD from the Chicago Medical School. She went on to complete her residency in internal medicine and fellowships in hematology/oncology and clinical pharmacology/pharmacogenomics at the University of Chicago. She has received national recognition for her research, including the Conquer Cancer Foundation/ASCO Young Investigator Award, the ASCPT Presidential Trainee Award, and selection for the ASH Clinical Research Training Institute. Dr. Pettit focuses on translational research and drug development for patients with myeloid malignancies, specifically myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia. Dr. Pettit is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Splenectomy. Dr. Pettit is board certified in Medical Oncology and Hematology.